期刊
CELL DEATH & DISEASE
卷 12, 期 10, 页码 -出版社
SPRINGERNATURE
DOI: 10.1038/s41419-021-04209-2
关键词
-
类别
资金
- Ministry of National Defense-Medical Affairs Bureau [MND-MAB-107-071, MND-MAB-110-058]
- Tri-Service General Hospital [TSGH-E-109213, TSGH-E-110189]
- Ministry of Science and Technology, Taiwan (R.O.C.) [MOST108-2635-B-016-001, MOST-110-2314-B-016-056, MOST109-2320-B-016-004]
The study identified miR-342-5p as downregulated in CML patients, which played a significant role in regulating cell proliferation and DNA double-strand breaks through targeting the CCND1 gene expression region, enhancing imatinib-induced apoptosis. The clinical database analysis further confirmed the association between miR-342-5p and predicted molecular responses in CML patients, suggesting its potential as a target for future treatment or prognostic evaluation.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome, and the current standard of care is the use of tyrosine kinase inhibitors (TKI). However, some patients will not achieve a molecular response and may progress to blast crisis, and the underlying mechanisms remain to be clarified. In this study, next-generation sequencing was used to explore endogenous miRNAs in CML patients versus healthy volunteers, and miR-342-5p was identified as the primary target. We found that miR-342-5p was downregulated in CML patients and had a significant inhibitory effect on cell proliferation in CML. Through a luciferase reporter system, miR-342-5p was reported to target the 3'-UTR domain of CCND1 and downregulated its expression. Furthermore, overexpression of miR-342-5p enhanced imatinib-induced DNA double-strand breaks and apoptosis. Finally, by analyzing clinical databases, we further confirmed that miR-342-5p was associated with predicted molecular responses in CML patients. In conclusion, we found that both in vivo and in vitro experiments and database cohorts showed that miR-342-5p plays a key role in CML patients, indicating that miR-342-5p may be a potential target for future CML treatment or prognostic evaluation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据